Navigation Links
Berger & Montague Announces Class Action Lawsuit Against Elan Corporation
Date:10/29/2008

PHILADELPHIA, Oct. 29 /PRNewswire-USNewswire/ -- Berger & Montague ("Berger") announced today that a class action lawsuit was filed in the United States District Court of New York on behalf of all purchasers of American Depository Shares (evidenced by American Depository Receipts) of Elan Corporation PLC ("elan" or the "Company") and all purchasers of options to purchase Elan securities during the period of June 17, 2008 through July 29, 2008 (the "Class Period") charging Elan and certain of its principal officers and directors with violations of the federal securities laws.

The complaint alleges that the Defendants materially misrepresented the facts about the results of a clinical study of a four ascending doses of a drug (bapineuzumab or AAB-001) that the Company and Wyeth were testing as a treatment for mild to moderate Alzheimer's disease.

The complaint alleges that the Defendants issued materially false and misleading representations stating that the 18 month clinical study of AAB-001, the Elan-Wyeth drug, produced "statistically significant and clinically meaningful benefits" in the 40-70% of patients with mild to moderate Alzheimer's disease who do not carry the gene that predisposes a person to Alzheimer's disease, as measured by four neuropsychological, mental and other Alzheimer's disease assessment scales.

These representations were materially misleading due to the facts disclosed at a medical conference on July 29, 2008, as follows:

(a) Typically, if a drug is effective higher doses of a drug correspond with increased efficacy. In the study of AAB-001 that did not occur. Indeed, patients did not even show a consistent pattern of benefit across the four different dosages that were administered in the trial.

(b) The lowest doses of AAB-001 worked better on some measures of cognition and function, while higher doses worked better on others, and sometimes doses in the middle produced worse results than placebo. This
'/>"/>

SOURCE Berger & Montague, P.C.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Longaberger Expands Horizon of Hope Campaign to Build Support for American Cancer Societys Breast Cancer Initiatives
2. Nationally Recognized Information Technology Veteran and Entrepreneur John Bamberger Joins gloStream, Inc. as Chief Channel Officer
3. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
4. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
5. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
6. HEI, Inc. Announces Sale of RFID Division Assets
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
8. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
9. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
10. Brooke Franchise Corporation Announces Selected July Results
11. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... New York, New York (PRWEB) May 29, 2015 ... and distributor of patented products, announces that it has ... Chat Room, a technology patent that aims to let ... various industry experts in real time. , "This is ... Expert Chat Room " said Scott J. Cooper, CEO ...
(Date:5/29/2015)... 2015 The print component of “Skin ... of approximately 250,000 and an estimated readership of 750,000. ... social media strategy, and across a network of top ... version of the campaign, click here. , ... Inside, the actress, model and producer details her skin ...
(Date:5/29/2015)... May 29, 2015 The campaign focuses ... as a number of specific concerns within, including the ... and mental health in the workplace. We are encouraged ... The campaign also brings special focus to people living ... speak up and seek help from healthcare professionals and ...
(Date:5/29/2015)... La Mirada, Ca (PRWEB) May 29, 2015 ... services, including pain consultations with specialists, physical therapy, ... who are experiencing mid back and/or lower back ... offering lumbar epidural injections for herniated discs, disc ... spine pain . , Healthpointe’s team of ...
(Date:5/29/2015)... The Global Allopurinol Industry Report ... the current state of the Allopurinol industry.With 147 ... on the state of the industry and is ... companies and individuals interested in the market. The ... including definitions, classifications, applications and industry chain structure. ...
Breaking Medicine News(10 mins):Health News:Licensing Alert! World Patent Marketing's Latest Blockbuster Licensing Deal Gets A New Twist on Technology With The Live Expert Chat Room 2Health News:Licensing Alert! World Patent Marketing's Latest Blockbuster Licensing Deal Gets A New Twist on Technology With The Live Expert Chat Room 3Health News:Licensing Alert! World Patent Marketing's Latest Blockbuster Licensing Deal Gets A New Twist on Technology With The Live Expert Chat Room 4Health News:Licensing Alert! World Patent Marketing's Latest Blockbuster Licensing Deal Gets A New Twist on Technology With The Live Expert Chat Room 5Health News:Mediaplanet Brings Activism to Those Living with Mental Illness in Bew “Mental Health Awareness” Campaign 2Health News:Healthpointe’s Pain Management Specialists Now Providing Lumbar Epidural Injections in Los Angeles County 2Health News:Healthpointe’s Pain Management Specialists Now Providing Lumbar Epidural Injections in Los Angeles County 3Health News:Allopurinol Industry (Global, China) 2015 Research Analysis and 2020 Forecasts 2
... Discovery shows how a group of molecules pulls certain ... a finding that could,help development of new cancer drugs, ... St.,Jude Children,s Research Hospital scientists offers new insights into ... could lead to new,cancer treatments., The researchers identified ...
... - Neurochem,(International) Limited (Neurochem), a wholly-owned subsidiary of ... that the Company has received an,acknowledgement from the ... response to the July 2007 approvable letter for ... the treatment of,Amyloid A (AA) amyloidosis is a ...
... Belinda Tsao-Nivaggioli,Chief Executive Officer of Avicena Group, Inc. ... featured in an exclusive interview,with http://www.wallst.net ... The interview,will be posted on http://www.wallst.net ... The interview will cover topics including Avicena Group,s ...
... University of Pennsylvania School of Medicine and other ... care providers can better their chances of identifying ... the way they ask patients questions., In a ... Internal Medicine, researchers found a number of communication ...
... malignancies at bay, research shows , , THURSDAY, Dec. 6 ... the key to cancer prevention, since new research shows ... reduce the risk of esophageal and bladder cancers. , ... Thursday at the American Association for Cancer Research,s Sixth ...
... Delays This Holiday Season May Lead to Kissing in ... flying during,the holidays normally conjures up images of screaming ... keep bumping,into your elbow with the drink cart. But ... Worst Airports to Make a Connection" study, which was,announced ...
Cached Medicine News:Health News:St. Jude Finds Mechanism for Faulty Protein Disposal 2Health News:Neurochem announces eprodisate (KIACTA(TM)) receives acknowledgement of complete response and is granted Class 2 review 2Health News:Neurochem announces eprodisate (KIACTA(TM)) receives acknowledgement of complete response and is granted Class 2 review 3Health News:WallSt.net Announces Upcoming Interview With CEO of Avicena Group 2Health News:Finding the right words: Provider-patient discussions can help domestic violence victims speak up 2Health News:Blackberries, Broccoli Sprouts Battle Cancer 2Health News:Blackberries, Broccoli Sprouts Battle Cancer 3Health News:Blackberries, Broccoli Sprouts Battle Cancer 4Health News:Philly International Airport Tops 'AXE's Best and Worst Airports to Make a Connection' 2Health News:Philly International Airport Tops 'AXE's Best and Worst Airports to Make a Connection' 3Health News:Philly International Airport Tops 'AXE's Best and Worst Airports to Make a Connection' 4Health News:Philly International Airport Tops 'AXE's Best and Worst Airports to Make a Connection' 5
(Date:5/28/2015)... YORK , May 28, 2015 /PRNewswire/ ... developing new drugs and tests, and this ... the instruments that can assist them. This according ... publisher. Kalorama Information said instruments such as mass ... assist in the identification of drug targets ...
(Date:5/28/2015)... , May 28, 2015  IRIDEX Corporation (NASDAQ: IRIX ... Officer James H. Mackaness is scheduled to present ... at 9:00 am PT in Los Angeles ... may be accessed on the Event Calendar of the Investors ... of the webcast will be available shortly after the conclusion ...
(Date:5/28/2015)... , May 28, 2015 ... the addition of the "United States Medical ... to their offering.      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ... in the United States ... Medical device manufacturers across the ...
Breaking Medicine Technology:Report: Proteomics Research Market Reaches $1.6 Billion 2Report: Proteomics Research Market Reaches $1.6 Billion 3United States Medical Adhesives Market Forecast and Opportunities, 2020 - New Medical Innovations with 3M, Henkel Adhesive Research, Ethicon and Cyberbond Dominating 2United States Medical Adhesives Market Forecast and Opportunities, 2020 - New Medical Innovations with 3M, Henkel Adhesive Research, Ethicon and Cyberbond Dominating 3
... -- The,first of two stages of the ... Kamada's Alpha-1 Antitrypsin (AAT) liquid drug,candidate for ... the treatment of patients suffering from AAT,deficiency. ... profiles,and patient tolerability, leading the way to ...
... WIRE)--Jun 1, 2007 - Arrowhead Research,Corporation (Nasdaq:ARWR) ... been published in the 2007 American Society ... The data are from,an ongoing Phase I ... and pharmacokinetics of its lead anti-cancer drug,candidate, ...
Cached Medicine Technology:PARI and Kamada Announce Positive Intermediate Phase I Results for,Inhaled Alpha-1 Antitrypsin 2PARI and Kamada Announce Positive Intermediate Phase I Results for,Inhaled Alpha-1 Antitrypsin 3Arrowhead Subsidiary, Insert, Publishes Interim Phase I Data from,Human Clinical Trials for New Cancer Drug 2Arrowhead Subsidiary, Insert, Publishes Interim Phase I Data from,Human Clinical Trials for New Cancer Drug 3
Sterile squares of smooth foil for repair of the floor of the orbit and other plastic surgery. Available in large size....
Clear Base Stand Magnifiers are ideal for any visual task that requires high magnification....
Bausch & Lomb magnifiers incorporates precision optics and patented ergonomic designs for increased clarity and comfort during use....
Ultra Thin Sheet. Medpor Sheets are commonly used for orbital floor reconstruction and other craniofacial applications....
Medicine Products: